AtaiBeckley (ATAI) Income towards Parent Company (2020 - 2026)
AtaiBeckley (ATAI) reported Income towards Parent Company of -$61.1 million for Q3 2025, down 129.03% on a YoY basis from $210.3 million in Q3 2024, and down 120.04% sequentially from -$27.8 million in Q2 2025.
AtaiBeckley (ATAI) Income towards Parent Company (2020 - 2026) Analysis & Trends
AtaiBeckley's Income towards Parent Company history runs 2 years deep, the most recent figure standing at -$29.8 million for Q1 2026.
- On a quarterly basis, Income towards Parent Company fell 12.61% year-over-year to -$29.8 million in Q1 2026; TTM through Mar 2026 was -$56.3 million, a N/A change from a year earlier, with the FY2025 full-year figure at -$659.9 million, down 344.64% from the prior year.
- Income towards Parent Company eased to -$61.1 million in Q3 2025, from -$27.8 million in the prior quarter.
- Across five years, Income towards Parent Company topped out at -$26.5 million in Q1 2025 and bottomed at -$29.8 million in Q1 2026.
- A 5-year average of -$30.4 million and a median of -$31.8 million in 2023 frame the typical range for Income towards Parent Company.
- Across the five-year window, Income towards Parent Company slumped 842.61% in 2021 and jumped 231.22% in 2023, its largest moves.
- Tracing ATAI's Income towards Parent Company over 5 years: stood at -$49.3 million in 2021, then advanced by 18.3% to -$40.3 million in 2022, then soared by 53.45% to -$18.7 million in 2023, then sank by 107.97% to -$39.0 million in 2024, then sank by 56.62% to -$61.1 million in 2025.
- Business Quant data shows ATAI's Income towards Parent Company at -$61.1 million in Q3 2025, -$27.8 million in Q2 2025, and -$26.5 million in Q1 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | AtaiBeckley | 1.56 Bn | 1.56 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -29.80 Mn |
| Sep 30, 2025 | -61.07 Mn |
| Jun 30, 2025 | -27.75 Mn |
| Mar 31, 2025 | -26.47 Mn |
| Mar 31, 2025 | -26.47 Mn |
| Dec 31, 2024 | -38.99 Mn |
| Sep 30, 2024 | -26.66 Mn |
| Jun 30, 2024 | -57.10 Mn |
| Mar 31, 2024 | -25.68 Mn |
| Dec 31, 2023 | -18.75 Mn |
| Sep 30, 2023 | 43.61 Mn |
| Jun 30, 2023 | -31.84 Mn |
| Mar 31, 2023 | -33.36 Mn |
| Dec 31, 2022 | -40.28 Mn |
| Sep 30, 2022 | -33.23 Mn |
| Jun 30, 2022 | -30.86 Mn |
| Mar 31, 2022 | -31.96 Mn |
| Dec 31, 2021 | -49.30 Mn |
| Sep 30, 2021 | -26.87 Mn |
| Jun 30, 2021 | -67.36 Mn |